RET and non-small cell lung carcinoma: The LIBRETTO‐321 study reported ORRs of 87.5% and 61.1% for selpercatinib in untreated and previously treated patients, respectively, confirming the satisfactory efficacy and safety of selpercatinib in Chinese patients with RET fusion NSCLC [27].